Adjuvant Therapy of Breast Cancer: Can We Do Better?
Author(s) -
Christoph Thomssen,
Wolfgang Janni
Publication year - 2009
Publication title -
breast care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.767
H-Index - 30
eISSN - 1661-3805
pISSN - 1661-3791
DOI - 10.1159/000250058
Subject(s) - medicine , breast cancer , disease , adjuvant , oncology , chemotherapy , cancer , basal (medicine) , adjuvant chemotherapy , insulin
Can We Talk About Cure? Our answer is yes and no. ‘Yes’, we can talk about curable disease in some cases. A 60-year-old woman diagnosed with steroid receptor-positive HER2 overexpressing breast cancer, today has a high probability to reach her 80th year of life. So, in this group of patients, we can realistically talk of a good chance to be cured. But also ‘No’, we cannot talk about a curable disease. There are still patients who have an unfavorable prognosis. A 44-year-old patient with a basal-like tumor, that does not regress well on aggressive neoadjuvant chemotherapy still has a high probability to die early from metastatic breast cancer. Although some new drugs are in development (e.g. PARP-inhibitors), currently we do not have good measures to change the fate of these patients. Here are still limits.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom